<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04671316</url>
  </required_header>
  <id_info>
    <org_study_id>DDS20-035BE</org_study_id>
    <nct_id>NCT04671316</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study Between &quot;DA-5209 Tab&quot; and &quot;Lixiana Tab&quot;</brief_title>
  <official_title>A Open-Label, Randomized, 6-sequence, 3-period, Fasting Condition, Singledose, Per Oral, Cross-over Study to Evaluate the Bioequivalence Between &quot;DA-5209 60mg Tab&quot; and &quot;Lixiana 60mg Tab&quot; in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-Label, Randomized, 6-sequence, 3-period, Fasting Condition, Single-dose, Per Oral,&#xD;
      Cross-over Study to Evaluate the Bioequivalence between &quot;DA-5209 60mg Tab&quot; and &quot;Lixiana 60mg&#xD;
      Tab&quot; in Healthy Volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Study design: An open-Label, randomized, 6-sequence, 3-period, fasting condition,&#xD;
           single-dose, per oral, cross-over study&#xD;
&#xD;
        2. Administration method:&#xD;
&#xD;
           The subject should maintain a minimum of 10 hours of empty stomach before&#xD;
           administration, and give an oral dose of 1 tablets (DA-5209 60mg) without water or&#xD;
           (DA-5209 60mg or Lixiana 60mg) with 150 mL of water at around 8 a.m. on the day of the&#xD;
           test. The subject should not chew or break the drug, but should swallow in whole with&#xD;
           water. The difference in administration time between the test subjects is about one&#xD;
           minute apart, considering the blood collection time.&#xD;
&#xD;
        3. Wash out period: at least 7 days&#xD;
&#xD;
        4. Blood collection time: Before the administration, 5, 10, 15, 30 min, 1, 1.5, 2, 3, 4, 6,&#xD;
           8, 12, 24, 48 hr after the administration (total 15 times)&#xD;
&#xD;
        5. Analysis: Measurement of the concentration of an unchangeable substance of Edoxaban in&#xD;
           plasma&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 23, 2020</start_date>
  <completion_date type="Actual">February 4, 2021</completion_date>
  <primary_completion_date type="Actual">February 4, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Crossover Assignment single-dose, 6-sequence, 3-period Bioequivalence Study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the plasma Concetration versus time curve(AUCt) of Edoxaban</measure>
    <time_frame>Before administration ~ 48hours</time_frame>
    <description>Area Under the plasma Concetration versus time curve(AUCt) of Edoxaban</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration(Cmax) of Edoxaban</measure>
    <time_frame>Before administration ~ 48hours</time_frame>
    <description>Peak Plasma Concentration(Cmax) of Edoxaban</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absorption rate constant(Ka) of Edoxaban</measure>
    <time_frame>Before administration ~ 48hours</time_frame>
    <description>Absorption rate constant(Ka) of Edoxaban</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of concentration compared to Maximum observed plasma concentration(Cmax) of Edoxaban</measure>
    <time_frame>Before administration ~ 48hours</time_frame>
    <description>% of concentration compared to Maximum observed plasma concentration(Cmax) of Edoxaban</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma drug concentration-time curve from time 0 to infinity(AUC∞) of Edoxban</measure>
    <time_frame>Before administration ~ 48hours</time_frame>
    <description>Area under the plasma drug concentration-time curve from time 0 to infinity(AUC∞) of Edoxban</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma drug concentration-time curve/Area under the plasma drug concentration-time curve from time 0 to infinity(AUCt/AUC∞) of Edoxaban</measure>
    <time_frame>Before administration ~ 48hours</time_frame>
    <description>Area under the plasma drug concentration-time curve/Area under the plasma drug concentration-time curve from time 0 to infinity(AUCt/AUC∞) of Edoxaban</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of peak concentration(Tmax) of Edoxaban</measure>
    <time_frame>Before administration ~ 48hours</time_frame>
    <description>Time of peak concentration(Tmax) of Edoxaban</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal phase of Half-life(t1/2) of Edoxaban</measure>
    <time_frame>Before administration ~ 48hours</time_frame>
    <description>Terminal phase of Half-life(t1/2) of Edoxaban</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>T1T2R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I: T1, &quot;DA-5209 60mg&quot; without water Period II: T2, &quot;DA-5209 60mg&quot; with 150mL water Period III: R, &quot;Lixiana 60mg&quot; with 150mL water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T1RT2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I: T1, &quot;DA-5209 60mg&quot; without water Period II: R, &quot;Lixiana 60mg&quot; with 150mL water Period III: T2, &quot;DA-5209 60mg&quot; with 150mL water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT1T2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I: R, &quot;Lixiana 60mg&quot; with 150mL water Period II: T1, &quot;DA-5209 60mg&quot; without water Period III: T2, &quot;DA-5209 60mg&quot; with 150mL water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT2T1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I: R, &quot;Lixiana 60mg&quot; with 150mL water Period II: T2, &quot;DA-5209 60mg&quot; with 150mL water Period III: T1, &quot;DA-5209 60mg&quot; without water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2RT1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I: T2, &quot;DA-5209 60mg&quot; with 150mL water Period II: R, &quot;Lixiana 60mg&quot; with 150mL water Period III: T1, &quot;DA-5209 60mg&quot; without water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2T1R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period I: T2, &quot;DA-5209 60mg&quot; with 150mL water Period II: T1, &quot;DA-5209 60mg&quot; without water Period III: R, &quot;Lixiana 60mg&quot; with 150mL water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-5209 60mg Tab</intervention_name>
    <description>single oral administration of 1 tablet of &quot;DA-5209 60mg Tab&quot; with 150mL water</description>
    <arm_group_label>RT1T2</arm_group_label>
    <arm_group_label>RT2T1</arm_group_label>
    <arm_group_label>T1RT2</arm_group_label>
    <arm_group_label>T1T2R</arm_group_label>
    <arm_group_label>T2RT1</arm_group_label>
    <arm_group_label>T2T1R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-5209 60mg Tab</intervention_name>
    <description>single oral administration of 1 tablet of &quot;DA-5209 60mg Tab&quot; without water</description>
    <arm_group_label>RT1T2</arm_group_label>
    <arm_group_label>RT2T1</arm_group_label>
    <arm_group_label>T1RT2</arm_group_label>
    <arm_group_label>T1T2R</arm_group_label>
    <arm_group_label>T2RT1</arm_group_label>
    <arm_group_label>T2T1R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixiana 60mg Tab</intervention_name>
    <description>single oral administration of 1 tablet of &quot;Lixiana 60mg Tab&quot; with 150mL water</description>
    <arm_group_label>RT1T2</arm_group_label>
    <arm_group_label>RT2T1</arm_group_label>
    <arm_group_label>T1RT2</arm_group_label>
    <arm_group_label>T1T2R</arm_group_label>
    <arm_group_label>T2RT1</arm_group_label>
    <arm_group_label>T2T1R</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A person who aged 19 or older at the time of screening&#xD;
&#xD;
          2. BMI of 18 to 30 (BMI calculation: kg/m2)&#xD;
&#xD;
             ◦Males or Females weighing 60kg or more&#xD;
&#xD;
          3. No congenital or chronic diseases or pathological symptoms&#xD;
&#xD;
          4. A person who is judged to be suitable for the study by the investigator based on the&#xD;
             clinical laboratory examination&#xD;
&#xD;
          5. A person who has fully understood the contents of the consent form for the study and&#xD;
             signed the consent form voluntarily and recorded the date of signature&#xD;
&#xD;
          6. A person who agreed to use contraception from the first administration of IP to a week&#xD;
             after the last administration of IP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A person who has taken a drug that significantly induces (e.g., barbital) or inhibits&#xD;
             the drug metabolic enzyme within 30 days prior to the first administration of IP&#xD;
&#xD;
          2. A person who has participated in other clinical trials within six months prior to the&#xD;
             first administration of the IP&#xD;
&#xD;
          3. A person who has had whole blood transfusion within 2 months or the apheresis within 2&#xD;
             weeks before the first administration of IP&#xD;
&#xD;
          4. A person who has medical history of gastric resection that can affect the drug&#xD;
             absorption&#xD;
&#xD;
          5. A person with a history of regular alcohol intake within a month prior to the first&#xD;
             administration of the IP:&#xD;
&#xD;
               -  Male: More than 21 cups/week&#xD;
&#xD;
               -  Female: More than 14 cups/week (1 cup: 50 ml of soju, 250 ml of beer, 30ml of&#xD;
                  spirits)&#xD;
&#xD;
          6. A person who is hypersensitive to any of the IP components, with clinically&#xD;
             significant bleeding, with end-stage renal disease and have kidney dialysis, with&#xD;
             hepatic disease related to blood coagulation disorder and clinically significant risk&#xD;
             of bleeding, with severe liver impairment, with an increased risk of bleeding, use&#xD;
             combination therapy with other anticoagulants, Severe hypertension factor, have&#xD;
             undergone artificial heart valve replacement&#xD;
&#xD;
          7. A person who has medical history of mental disease&#xD;
&#xD;
          8. A person who is judged not to be suitable for the study by the investigator&#xD;
&#xD;
          9. Lactating or possibly pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SeungHyun Kang, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>H Plus Yangji Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H Plus Yangji Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08779</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

